Over the last decade, an increasing number of clinical trials in cancer research have been incorporating a health-related quality of life (HRQoL) instrument as part of their trial design. In this article the authors discuss the validity and usefulness of a new HRQoL instrument already in use in the United States.
Unraveling our understanding of cancer stem cells and their role in the development and progression of acute myeloid leukemia could lead to improved outcomes.
Pancreatic cancer is a challenging disease due to its high rates of resistance to traditional chemotherapy and radiotherapy. There has been little improvement in the prognosis of pancreatic cancer cases in the past decades, highlighting the need for more effective therapeutic approaches. This article summarizes current developments in targeted pancreatic cancer drug delivery, focusing on delivery systems, targets, and therapeutic agents.
A systematic search of literature was conducted, and studies providing data on the effectiveness of current and/or future drugs used in the treatment of metastatic melanoma were selected for review. This review discusses the advantages and limitations of these agents, evaluating past, current and future clinical trials designed to overcome such limitations.
